The Japanese health ministry has withdrawn a sakigake fast-track designation for Eisai’s biliary tract cancer drug E7090, a fibroblast growth factor receptor (FGFR) inhibitor, after another drug in the same class of medicines was approved earlier this year. E7090 earned…
To read the full story
Related Article
- Eisai Files Tasurgratinib for Biliary Tract Cancer in Japan
December 19, 2023
REGULATORY
- Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
April 9, 2026
- Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
April 9, 2026
- Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
- Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
April 9, 2026
- MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





